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Many medications have been developed for one purpose 
but then are found to have other clinical activities. For 
example, minoxidil was originally developed as an anti-
hypertensive but then was found to cause excessive hair 
growth. Because of the multiple potential pathways that 
can be involved with cancer growth and metastases, 
tremendous interest remains in whether currently used 
non-cancer medications may potentially have anti-cancer 
eﬀ  ects. In this review article, we will present and evaluate 
the evidence for several commonly used over-the-
counter and prescription medications that have been 
evaluated among breast cancer survivors in prospective 
studies. Please note that we have not included a 
discussion of selective serotonin reuptake inhibitors and 
tamoxifen, since this appears to be more of a pharma  co-
logic interaction rather than a true anti-cancer eﬀ  ect. We 
have focused our discussion on drugs that may inﬂ  uence 
cancer recurrence rather than primary incidence.
Methods
For this review article, we will focus on cohort studies, 
prospective nested case control studies, and randomized 
controlled trials that presented breast cancer-speciﬁ  c 
survival or recurrence data. We have omitted case control 
studies because these can be subject to bias. For our 
search strategy, we searched PubMed through July 2012 
for relevant English language studies. Th  e major search 
terms used were breast neoplasms and (mortality or 
survival or survival analysis or survivors or recurrence). 
For the individual drug search terms, we used (aspirin or 
anti-inﬂ  ammatory agents, non-steroidal), adrenergic beta-
antagonists, (angiotensin-converting enzyme inhibitors or 
angiotensin receptor antagonists), (insulin or hypo  gly-
cemic or metformin), (statin or lovastatin or simvastatin 
or ﬂ  uvastatin or atorvastatin or pravastatin or rosuva-
statin), and (digoxin or digitalis). We also reviewed the 
references lists of all relevant papers for any additional 
studies. We did not include studies that were presented 
only in abstract form at a meeting or were published only 
as editorial letters.
Aspirin and other non-steroidal anti-infl  ammatory 
drugs
Biological rationale/preclinical data
Aspirin and non-steroidal anti-inﬂ  ammatory  drugs 
(NSAIDs) may inﬂ  uence breast cancer recurrence through 
a number of mechanisms. Th  ey inhibit production of 
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© 2012 BioMed Central Ltdprostaglandins and cyclo-oxygenase (COX), which comes 
in two isoforms: COX-1 and COX-2 [1]. It has been 
known for over 20  years that elevated tissue levels of 
prostaglandins have been seen in breast tissue, especially 
hormone receptor-negative tumors [2]. Prostaglandins 
can stimulate angiogenesis [3] and inhibit apoptosis [4]. 
In addition, prostaglandins stimulate aromatase activity 
and thus may aﬀ  ect estrogen production [5]. Aromatase 
is an enzyme that catalyzes the conversion of androgen 
precursors to estrogen, the main source of estrogen 
production in post-menopausal women. Aromatase inhi-
bitors are widely used for breast cancer treatment and 
lower estrogen levels. Aspirin and NSAIDs could im-
prove survival if they acted as aromatase inhibitors. 
Cross-sectional studies provide suggestive evidence that 
aspirin can inﬂ  uence estrogen levels, since estrogen levels 
are lower among women using aspirin [6]. However, 
prostaglandin eﬀ   ects may not be limited to hormone 
receptor-positive tumors.
Th   ere is also strong evidence that aspirin and NSAIDs 
may prevent early metastasis but not advanced disease. 
COX-2 overexpression has been associated with human 
breast cancer that has metastasized [7]. Th   is may explain 
why early trials of NSAIDs to treat advanced or meta-
static breast cancer showed little eﬀ   ect [8]. A recent 
publication reviewed the extensive experimental evi-
dence showing that platelets promote adhesion of 
circulating tumor cells to the endothelium and protect 
them from immune elimination within the circulatory 
system, thus enabling future establishment of metastases. 
Aspirin, but not NSAIDs, inhibits platelet function [9].
Epidemiologic data
Th   ree out of four large prospective observational studies 
have shown a potential survival beneﬁ  t among women 
with breast cancer who use aspirin or NSAIDs. Kwan and 
colleagues [10] reported from the Life After Cancer 
Epidemiology (LACE) study, a prospective cohort of 
2,292 survivors whose stage I to III breast cancer was 
diagnosed between 1997 and 2000 and who were drawn 
primarily from Kaiser Permanente Northern California. 
Th  e authors found a reduced risk of recurrence for 
current regular (>3  days per week) use of ibuprofen 
(relative risk (RR) = 0.56, 95% conﬁ  dence interval (CI) = 
0.32 to 0.98) but not aspirin (RR = 1.09, 95% CI = 0.74 to 
1.61). However, short follow-up (mean of 2.5 years) may 
have precluded the detection of an association. Blair and 
colleagues [11] reported a borderline reduced risk of 
breast cancer death (RR = 0.64, 95% CI = 0.39 to 1.05) for 
any use of NSAIDs (aspirin and non-aspirin NSAIDs 
combined) after diagnosis among 591 post-menopausal 
women with breast cancer and a reduced risk of breast 
cancer death for aspirin use alone (RR = 0.53, 95% CI = 
0.30 to 0.93). In the combined group of any NSAID use, 
use of aspirin only (43%) was considerably more common 
than use of non-aspirin NSAIDs only (10%) or use of 
both (27%). In the Nurses’ Health Study [12], we reported 
on 4,164 women with early-stage breast cancer and found 
a reduced risk of breast cancer death for aspirin use after 
diagnosis (RR = 0.51, 95% CI = 0.41 to 0.65). Th  e  survival 
beneﬁ  t was similar for estrogen receptor (ER)-positive 
and -negative tumors. Th  ere was a suggestion of a 
protective association with NSAID intake as well, but 
power was limited. Intriguingly, among a subset of 2,001 
subjects for whom we had tumor samples to perform 
COX-2 immunohisto  chemistry, we found a similar 
association for aspirin use among those with COX-2-
positive tumors (RR = 0.64, 95% CI = 0.43 to 0.96) and 
COX-2-negative tumors (RR  = 0.57, 95% CI  = 0.44 to 
0.74), suggesting that the aspirin mechanism for breast 
cancer may be independent of COX-2 [7]. Aspirin binds 
covalently to and inhibits both COX-1 and COX-2. In 
breast carcinogenesis, in contrast to colon cancer, COX-1 
activity may be relatively more important [13].
Among 1,024 breast cancer cases from a population-
based case control study followed as a cohort for an 
average of 7 years, Li and colleagues [14] reported a non-
statistically signiﬁ  cant reduced risk of overall mortality 
among those using aspirin (RR = 0.82, 95% CI = 0.54 to 
1.24) and a similar risk for breast cancer mortality (RR = 
0.89, 95% CI = 0.53 to 1.52).
In addition to the prospective studies, randomized trial 
data have demonstrated an eﬀ  ect of aspirin on cancer 
recurrence. In the UK, Rothwell and colleagues [15] 
pooled data from ﬁ  ve large randomized trials of aspirin 
to prevent vascular disease. Th  e purpose of the pooled 
analysis was to examine the eﬀ  ect of aspirin on cancer 
metastases presenting during or after the trials’ follow-
up. In the pooled data, those subjects allocated to aspirin 
had a reduced risk of cancer with distant metastasis, 
mainly due to a reduced risk of metastatic adeno-
carcinoma (RR = 0.52, 95% CI = 0.35 to 0.75). In addition, 
patients with adenocarcinoma who did not have 
metastasis at initial diagnosis and who remained on 
aspirin up to or after diagnosis had a markedly reduced 
risk of metastasis during follow-up (RR = 0.31, 95% CI = 
0.15 to 0.76). Examination of case fatality by individual 
cancers was hampered by small numbers, but there was a 
suggestion of reduced case fatality for breast cancer 
(RR  = 0.16, 95% CI  = 0.02 to 1.19). Because these 
dramatic pooled ﬁ  ndings were similar in the one trial 
which used a low-dose (75 mg) slow-release formulation 
of aspirin designed to inhibit platelet function only in the 
portal circulation and not to have systemic eﬀ  ects, the 
authors speculate that aspirin’s eﬀ  ect on platelet-medi  ated 
formation of metastases is the likely mechanism [15].
Corro  boration was provided by a linked meta-analysis 
comparing data from observational studies with those 
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with distant metastases pooled from observational 
studies (RR = 0.58, 95% CI = 0.20 to 1.71) was similar to 
that found in randomized trials but, owing to small 
numbers, did not reach statistical signiﬁ  cance [16].
In conclusion, abundant preclinical and epidemiologic 
data support a protective role for aspirin and NSAIDs in 
breast cancer survival [10-12,16]. In addition, pooled 
data from ﬁ  ve large randomized trials of aspirin used to 
prevent vascular disease have demonstrated a reduced 
risk of metastatic and fatal adenocarcinoma, including 
breast cancer, among those allocated to aspirin. Results 
from the randomized trials hint that low-dose (75 mg) 
aspirin may be eﬀ   ective, suggesting that inhibition of 
platelet function may be the key mechanism in 
preventing metastases [15]. However, as we reported in a 
previous review, several other mecha  nisms may be 
involved for breast cancer [6]. Although COX-2 
expression is strongly linked to the cancer process, for 
breast cancer these beneﬁ  cial eﬀ  ects are not solely or 
primarily caused by inhibiting COX-2 [7]. Although non-
aspirin NSAIDs may also improve breast cancer survival, 
evidence is currently strongest for aspirin [13,15].
Beta-blockers
Biological rationale/preclinical data
Patients and clinicians have shown great interest in the 
possible link between stress and cancer initiation and 
progression. In a 2006 review, Antoni and colleagues [17] 
elucidated how bio-behavioral inﬂ  uences (for example, 
life stress, psychological processes, and health behaviors) 
could plausibly aﬀ   ect cancer processes through neuro-
endocrine pathways. In fact, evidence is stronger for an 
eﬀ  ect on cancer progression than on cancer initiation [17].
Th  e major neuroendocrine transmitters of the stress 
response are catecholamines, and beta-adrenergic recep-
tors mediate most of the eﬀ   ects of catecholamines. 
Preclinical studies in several types of cancer (ovarian, 
nasopharyngeal, prostate, and pancreatic) have shown 
catecholamine stimulation to increase angiogenesis, 
tumor invasion, metastasis, and inhibit apoptosis; many 
of these eﬀ  ects could be inhibited by the use of beta-
adrendergic blocker drugs such as propranolol [18].
In a recently published study, mice with mammary 
cancer subjected to chronic stress had neuroendocrine 
activation that did not aﬀ   ect growth of the primary 
tumors but increased distant metastases 30-fold. Th  is 
tumor spread could be inhibited by treatment with 
propranolol [19]. Beta-adrenergic receptors have been 
found in human breast cancer cells [20].
Epidemiologic data
Four observational studies among women with breast 
cancer (three cohorts and one prospective nested case 
control) have examined the association between intake of 
beta-blockers and risk of either breast cancer mortality 
or recurrence. In 2010, Powe and colleagues [21] reported 
on 466 stage I to III UK breast cancer patients with more 
than 10  years of follow-up; 92 (20%) had pre-existing 
hypertension and 43 of these (9%) were treated with beta-
blockers. In multivariate models controlling for age and 
tumor characteristics, women using beta-blockers had 
marked decreases in breast cancer mortality (RR = 0.29, 
95% CI = 0.12 to 0.72) and distant recurrence (RR = 0.43, 
95% CI = 0.20 to 0.93) [21]. Th   is initial small study was 
rapidly followed by three larger ones published in 2011. 
Melhem-Bertrandt and colleagues [22] reported on 1,413 
patients with stage I to III breast cancer at the MD 
Anderson Cancer Center; 102 (7%) used beta-blockers. 
Th  e authors hypothesized that the higher prevalence of 
abdominal obesity and metabolic syndrome among 
women with triple-negative breast cancer and its link to 
adrenergic dysregulation and also high expression of 
beta-adrenergic receptors in triple-negative breast cancer 
cell lines could make these patients particularly sensitive 
to beta-blocker treatment. Th  e authors reported a 
decreased risk of relapse (RR = 0.52, 95% CI = 0.31 to 
0.88) for users of beta-blockers among all patients. Th  is 
was most pronounced among the 377 patients with 
triple-negative breast cancer (RR = 0.30, 95% CI = 0.10 to 
0.87) [22]. Ganz and colleagues [23] reported on 1,779 
women with stage I to IIIA breast cancer from the LACE 
cohort, all of whom had linked pharmacy records. Mean 
follow-up was 8.2 years, and 270 of the women (15%) 
used beta-blockers. Th  e authors found non-statistically 
signiﬁ  cant decreased risks of breast cancer death (RR = 
0.76, 95% CI = 0.44 to 1.33) and recurrence (distant, loco-
regional, or contralateral, RR = 0.85, 95% CI = 0.57 to 
1.32) among users of beta-blockers [23]. Th   e fourth study 
is a nested case control reported by Barron and 
colleagues [24] linking the Irish national cancer registry 
and pharmacy registries. Th   ey studied 5,333 women with 
stage I to IV breast cancer. Five hundred ninety-ﬁ  ve beta-
blocker users (70 using propranolol and 525 using 
atenolol) were matched 1:2 on factors asso  ciated with 
breast cancer screening and other healthy behaviors 
(including socioeconomic status, smoking, aspirin, and 
statin use) to controls not using a beta-blocker. Th  e 70 
propranolol users had a markedly decreased risk of breast 
cancer mortality (RR  = 0.19, 95% CI  = 0.06 to 0.60) 
compared with non-beta-blocker users, but this was 
based on only four breast cancer deaths among 
propranolol users. Propranolol users also were less likely 
to present with locally advanced or metastatic tumors. 
No such association was seen for atenolol [24]. 
Propranolol is non-selective and blocks both beta-1 and 
beta-2 adrenergic receptors, whereas atenolol blocks only 
beta-1. Historically, over time, patterns of use have 
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(beta-1) blockers. Th   e authors present preclinical 
evidence that beta-2 signaling may be more important 
for cancer metastasis, and their results would seem to 
bolster this hypothesis [24].
In conclusion, tantalizing evidence from preclinical 
studies supports a role for beta-blockers to inhibit breast 
cancer metastasis and potentially improve survival. 
Observational studies are hampered by a relatively low 
prevalence (approximately 10% to 15%) of beta-blocker 
use and the fact that only a subset of non-selective beta-
blockers may be eﬀ  ective, and these have been used less 
over time. Additionally, the beta-blocker eﬀ  ect may diﬀ  er 
by tumor subtype, with a stronger eﬀ   ect seen among 
triple-negative tumors.
Angiotensin-converting enzyme inhibitors and 
angiotension type I receptor blockers
Biological rationale/preclinical data
Th   e renin-angiotensin-aldosterone system (RAAS) has a 
potential role in breast cancer control. Angiotensin I is 
cleaved into angiotensin II by angiotensin-converting 
enzyme (ACE). Angiotensin II interacts with angiotensin 
type I receptors to promote aldosterone secretion and 
vasoconstriction. ACE inhibitors (ACEIs) and angio  ten-
sin type I receptor blockers (ARBs) are commonly used 
to treat hypertension, congestive heart failure, and 
chronic kidney disease [18].
Polymorphisms of the RAAS genes leading to increased 
activity of the system have been associated with increased 
risk of breast cancer [25,26]. Breast cancer cells have 
been found to express components of the RAAS [27]. 
RAAS stimulation of breast cancer cells can increase cell 
proliferation via protein kinase C activation and epider-
mal growth factor receptor transactivation as well as 
activating the P13K-kinase B (AKT) pathway [28,29]. 
RAAS stimulation of hormone receptor-negative breast 
cancer cells has been shown to increase expression of 
angiogenesis-related genes [27].
Epidemiologic data
Two observational studies that previously reported on 
use of beta-blockers and breast cancer survival also 
reported on ACEI/ARB use. Contrary to the hypotheses 
generated by the preclinical evidence, neither the MD 
Anderson cohort of 1,413 patients reported by Melhem-
Bertrandt and colleagues [22] nor the LACE cohort (n = 
1,779) reported by Ganz and colleagues [23] found any 
evidence of decreased recurrence, breast cancer 
mortality, or total mortality among women with breast 
cancer using ACEIs or ARBs (Table 1) [22,23]. In fact, an 
elevated risk of recurrence was found among the LACE 
cohort (RR  = 1.56, 95% CI  = 1.02 to 2.39) [23]. In a 
smaller cohort of 703 stage II/III breast cancer patients 
from Albert Einstein Medical Center, Chae and 
colleagues [30] reported a reduced risk of breast cancer 
recurrence among those using ACEI/ARB (RR  = 0.49, 
95% CI  = 0.31 to 0.76), but total mortality was not 
reduced. Th   erefore, despite promising preclinical evi  dence 
for ACEIs/ARBs, substantial evidence for a protective 
eﬀ   ect among women with breast cancer is currently 
lacking.
Statins
Biological rationale/preclinical data
Statins – HMG-CoA (3-hydroxy-3-methyl-glutaryl-CoA) 
reductase inhibitors – are widely used lipid-lowering 
drugs. Interestingly, lipophilic statins (for example, simvi-
statin, lovastatin, and ﬂ  uvastatin) have been shown in 
vitro to inhibit breast cancer cell growth and proliferation 
with a variety of hypothesized mechanisms. In multiple 
cell lines, statins can inhibit prenylation (post-trans-
lational modiﬁ   cation) of multiple proteins, including 
those in the Ras family, which is involved in signal trans-
duction and presumed to be important in carcinogenesis 
[31]. Statins may also inhibit histone deacetylase activity 
[32]. Drugs targeting histone deacetylation are already 
approved for lymphoma and have activity in other 
cancers as well. Several clinical trials in cancers other 
than breast cancer have suggested that statins used in 
conjunction with chemotherapy may improve eﬃ   cacy 
[18]. In terms of breast cancer incidence, studies on the 
eﬀ  ects of statins are mixed. However, the only published, 
cohort studies on the association between statins and 
breast cancer recurrence have consistently shown a 
decreased risk of recurrence.
Epidemiologic data
Th  e ﬁ   rst published study used the LACE population. 
Statin use was conﬁ   rmed via pharmacy records, and 
health outcomes were veriﬁ   ed by questionnaire and 
medical record review. Use of statins for more than 
100 days after diagnosis compared with shorter-term use 
was associated with a non-signiﬁ  cant decreased risk of 
cancer recurrence (RR = 0.67, 95% CI = 0.39 to 1.13) after 
adjustment for age at diagnosis, race, body mass index 
(BMI), cancer stage, and tamoxifen use. Breast cancer 
recurrence risk decreased with increasing duration of 
post-diagnosis statin use (P for trend = 0.02). However, 
power was limited, as there were only 16 recurrences 
among survivors who used statins more than 100 days 
after diagnosis. Th  e primary statin used in this cohort 
was the lipophilic lovastatin, which accounted for 84% of 
statin use among regular statin users [33]. Th   e study by 
Chae and colleagues [30], which was previously cited on 
ACEI/ARB, also evaluated the association with statin use 
and reported a decrease risk of recurrence (multivariate 
hazard ratio (HR) = 0.40, 95% CI = 0.24 to 0.67) and no 
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breast cancer survival
     Number      Breast  cancer  Total
      taking drug  Years of  Recurrence  mortality  mortality
Authors (year)  Study population  Number  (percentage)  follow-up  RR (95% CI)  RR (95% CI)  RR (95% CI)
Aspirin
Kwan et al. [10] 
(2007)
LACE cohort, stages I-IIIA, with 
linked pharmacy records
2,292 - Mean 2.5 1.09a 
(0.74-1.61)
--
Blair et al. [11] 
(2007)
Iowa Women’s Health Study, 
post-menopausal 
591 - Maximum 9.5 - 0.53 
(0.30-0.93)
0.53 
(0.36-0.79)
Holmes et al. [12] 
(2010)
Nurses’ Health Study, stages I-III 4,164 (48% of the 
person-time)
Maximum 30 - 0.51 
(0.41-0.65)
-
Li et al. [14] 
(2012)
Cases from a population-based 
case control study followed as 
a cohort
1,024 - Mean 7.3 - 0.89 
(0.52-1.52)
0.82 
(0.54-1.24)
Beta-blockers
Powe et al. [21] 
(2010)
UK, stages I-III 466 43 (9%) Mean 10.3 0.43b 
(0.20-0.93)
0.29 
(0.12-0.71)
-
Melhem-Bertrandt 
et al. [22] (2011)
MD Anderson triple-negative 
stages I-III
1,413 102 (7%) Median 4.6 0.52a 
(0.31-0.88)
- 0.64 
(0.38-1.07)
Ganz et al. [23] 
(2011)
LACE cohort, stages I-IIIA, with 
linked pharmacy records
1,779 270 (15%) Mean 8.2 0.86a 
(0.57-1.32)
0.76 
(0.44-1.33)
1.04 
(0.72-1.51)
Barron et al. [24] 
(2011)
Nested case control linked Irish 
cancer and pharmacy registries, 
stages I-IV
5,333 Propranolol = 70 
Atenolol = 525 
(matched 1:2)
Median 3.5 -
-
0.19 
(0.06-0.60)
1.16 
(0.84-1.61)
-
-
Angiotensin-converting enzyme inhibitors (ACEIs) and angiontensin type I receptor blockers (ARBs)
Melhem-Bertrandt 
et al. [22] (2011)
MD Anderson triple-negative 
stages I-III
1,413 140 (10%)c Median 4.6 0.82a 
(0.54-1.26)
- 0.99 
(0.65-1.51)
Ganz et al. [23] 
(2011)
LACE cohort, stages I-IIIA, with 
linked pharmacy records
1,779 137 (8%)d Mean 8.2 1.56a 
(1.02-2.39)
1.27 
(0.74-2.19)
1.23 
(0.82-1.83)
Chae et al. [30] 
(2011)
Stage II/III hospital patients 703 168 (24%) Median 4.6 0.49a 
(0.31-0.76)
-N S
Statins
Kwan et al. [33] 
(2008)
LACE cohort, stages I-IIIA, with 
linked pharmacy records
1,811 367 (20%) Mean 5.0 0.67a 
(0.39-1.13)
--
Ahern et al. [34] 
(2011)
Danish registry cohort with 
linked pharmacy records, 
stages I-III
18,769 140 (10%)c Median 6.8 0.83a 
(0.70-0.98)
--
Chae et al. [30] 
(2011)
Stage II/III hospital patients 703 156 (22%) Median 4.6 0.40a 
(0.24-0.67)
-N S
Metformin
He et al. [42] 
(2012)
MD Anderson HER2-positive 
stages II-IV
1,983 66 (3.3%) Median 4.0 - 0.47 
(0.24-0.90)
0.52 
(0.28-0.97)
Bayraktar et al. [46] 
(2012)
MD Anderson, triple-negative 
on adjuvant chemotherapy, 
stages I-III
1,448 63 (4.4%) 
meformin, 67 
(4.6%) on other 
anti-diabetics
Median 5.2 1.63b 
(0.87-3.06) 
for diabetics not 
on metformin, 
compared with 
diabetics on 
metformin
1.22 
(0.66-2.28) 
for diabetics not 
on metformin, 
compared with 
diabetics on 
metformin
Currie et al. [44] 
(2012)
UK, patients with solid tumors, 
including breast cancer 
stages I-IV 
112,408 
(25,575 
breast cancer)
1,428 (1.3%) 
metformin alone, 
1,125 (1.0%) 
metformin + 
sulfonylurea 290 
(0.3%) metformin 
+ insulin
Mean 9.3, 
median 
6.8 (overall 
survival)
- - 0.96e 
(0.64-1.43)
aAny recurrence; bdistant recurrence; cACEI or ARB use; dACEI only; ebreast cancer survivors only; see [44] for all cancer survivor numbers. CI, confi  dence interval; LACE, 
Life After Cancer Epidemiology; NS, not signifi  cant; RR, relative risk.
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study, as there were only 19 recurrences among those 
who used statins at least 6 months [30].
Th  e largest study to date was a population-based 
Danish cohort of 18,769 survivors of stage I to III breast 
cancer diagnosed between 1996 and 2003. Statin use was 
assessed via linkage to the National Registry of Medicinal 
Products, which tracks all prescriptions since 1995. 
Breast cancer recurrence was conﬁ   rmed via cancer 
registry data. Women who used primarily lipophilic 
statins had a lower risk of recurrence compared with 
non-users (10-year HR = 0.73, 95% CI = 0.60 to 0.89) 
after adjustment for age at diagnosis, menopausal status, 
cancer stage, ER status, cancer treatment, and use of 
other relevant non-prescription medications. In contrast, 
women who used primarily hydrophilic statins (for 
example, atorvastatin, pravastatin, or rosuvastatin) had 
the same risk of breast cancer recurrence as non-users 
(10-year adjusted HR = 1.2, 95% CI = 0.79 to 1.70). It 
should be noted that the analyses with hydrophilic statins 
were limited for power; there were only 39 recurrences at 
10 years compared with 182 recurrences among users of 
lipophilic statins. Th   e primary statin used in the Danish 
cohort was simvastatin (accounting for 72% of prescrip-
tions among statin users), which is the most lipophilic 
statin. Stratiﬁ  ed models showed no diﬀ  erence by grade, 
ER status, or type of treatment [34]. In the US, prior to 
the introduction of the generic statins in 2006, Lipitor 
(atorvastatin; Pﬁ  zer Inc, New York, NY, USA) had the 
largest market share [35].
Although the pharmacologic diﬀ  erences between lipo-
philic and hydrophilic statins in terms of their cholesterol-
lowering eﬀ   ects have been well characterized, less is 
known about statins’ pleiotropic eﬀ  ects. Hydrophilic, but 
not lipophilic, statins may increase mevalonate synthesis 
in extra-hepatic tissues and this may result in diﬀ  erential 
eﬀ   ects on cancer development. Lipophilic statins also 
tend to accumulate more in fat and have higher plasma 
protein binding than hydrophilic statins, and this could 
result in more extra-hepatic activity and systemic eﬀ  ects 
[36].
In summary, the observational data on statins inﬂ  u-
encing breast cancer recurrence risk are compelling and 
provide a strong justiﬁ   cation for a randomized trial. 
Furthermore, similar to the aspirin data, data from the 
multiple randomized trials of statins for cardiovascular 
disease prevention/treatment should be pooled to 
evaluate for possible eﬀ  ects on cancer recurrence and 
mortality.
Digoxin
Biological rationale/preclinical data
Cardiac glycosides (the most widely used of which is 
digoxin) have also demonstrated anti-tumor eﬀ  ects  in 
vitro, presumably through inhibition of Na+K+-ATPase. A 
variety of anti-tumor eﬀ   ects, including induction of 
apoptosis and inhibition of DNA topoisomerase II, have 
been observed in cell lines [18,37,38].
Epidemiologic data
Only one study (which has been published several times 
at varying times of follow-up) has evaluated the asso  cia-
tion between breast cancer recurrence and digoxin use. 
With 22 years of follow-up, breast cancer survivors who 
used digoxin had a lower rate of death (6%, n = 32) from 
breast cancer than non-users (34%, n = 143) [39]. To date, 
no other study on this topic has been published.
Anti-diabetic medications
Biological rationale/preclinical data
Although insulin, sulfonylureas, thiazolidinediones, and 
metformin all lower glucose levels and have been used 
successfully for diabetes treatment, they have diﬀ  erent 
mechanisms of action and diﬀ   erent associations with 
breast cancer survival. In terms of its anti-diabetic eﬀ  ect, 
metformin inhibits hepatic gluconeogenesis and improves 
insulin sensitivity in peripheral tissue [40]. Th  e mecha-
nism of action for thiazolidinediones (for example, 
rosiglitazone) is not completely understood, but they 
increase glucose utilization in adipose, muscle, and 
hepatic tissue, most likely by activating peroxisome 
proliferator-active receptors (PPARs). Both metformin 
and thiazolidinediones are associated with lower fasting 
insulin and C-peptide levels. Importantly, insulin is a 
known mitogen and can activate insulin-like growth 
factor 1 (IGF-1) receptors. Sulfonylureas stimulate the 
release of insulin from pancreatic beta cells. Higher 
circu  lating insulin has been associated with worse breast 
cancer mortality [41]. Since most of the studies that have 
evaluated the eﬀ   ect of anti-diabetic medications on 
cancer survival have compared recurrence risks across 
categories of drugs, all classes will be discussed 
concurrently [42].
Epidemiologic data
Because of the important biologic diﬀ  erences among the 
anti-diabetic medications, in addition to the overall 
search criteria, we limited our review to studies that 
reported results separately for types of anti-diabetic 
medication. In addition, we reviewed an intriguing study 
looking at pathologic complete response rates by anti-
diabetic medication use. Interestingly, the studies have 
been surprisingly consistent, showing a decreased risk of 
all-cancer mortality among diabetics who use metformin 
compared with those who use sulfonylureas or insulin. 
For a variety of reasons, these observational studies can 
be challenging to interpret. Diabetics have greater 
comorbidity and shorter life expectancy and so may get 
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have a higher risk of adverse events from treatments [43]. 
In addition, the use of certain anti-diabetic drugs may be 
associated with certain prognostic factors. For example, 
metformin users tend to be younger than subjects who 
use other anti-diabetic medications. Analyses are further 
complicated by the fact that diabetic patients switch back 
and forth over time between mono-therapy and 
combined therapy.
Th  e study with the largest number of breast cancer 
cases was a retrospective study of 112,408 subjects from 
the UK with a diagnosed solid tumor; 8,392 of the 
subjects had type II diabetes. Medication use was con-
ﬁ   rmed with pharmacy records. Among 25,575 breast 
cancer survivors (1,182 with type II diabetes), there was 
an increased risk of breast cancer mortality associated 
with having type II diabetes (unadjusted HR = 1.32, 95% 
CI  = 1.17 to 1.49). However, metformin use among 
cancer survivors was associated with a decreased risk of 
overall mortality (adjusted HR = 0.85, 95% CI = 0.78 to 
0.93) compared with non-diabetics. In contrast, diabetics 
who used sulfonylureas (HR  =  1.13, 95% CI  = 1.05 to 
1.21) or insulin (HR = 1.13, 95% CI = 1.01 to 1.27) had an 
increased risk of mortality. Th  ese diﬀ  erences were not 
signiﬁ    cant in analyses limited to breast cancer survivors 
[44]. In two companion studies, investigators from MD 
Anderson focused on outcomes among speciﬁ  c breast 
cancer subgroups. In the ﬁ  rst study, they retrospectively 
reviewed 1,983 consecutive patients with stage II to IV 
HER2-positive breast cancer (154 diabetics) and found 
again that diabetes was associated with worse overall 
survival (adjusted HR  =  1.42, 95% CI  = 1.04 to 1.94). 
However, in multivariate analyses, survival diﬀ  ered by 
anti-diabetic therapy, and insulin users had a shorter 
survival than diabetics who did not use insulin and non-
diabetics. In contrast, diabetics who used metformin had 
signiﬁ  cantly longer survival compared with diabetics who 
did not use metformin or non-diabetics. In multivariate 
analyses, both metformin use and thiazolidinedione use 
were associated with improved survival after adjustment 
for age, BMI, ER status, and use of insulin or insulin 
secretagogue therapy. In an analysis of competing risks 
among diabetic patients, metformin and thiazolidino-
diones were associated with decreased breast cancer-
speciﬁ   c mortality [42]. Th  e second study focused on 
triple-negative breast cancer and included 1,448 women 
(including 63 diabetics on metformin and 67 diabetics 
not on metformin) with stage I to III triple-negative 
breast cancer treated with adjuvant chemo  therapy 
between 1995 and 2007. In multivariate analyses, both 
diabetics not on metfomin and non-diabetics had a non-
signiﬁ   cant increased risk of distant metastases (HR  = 
1.63, 95% CI = 0.87 to 3.06 and HR = 1.62, 95% CI = 0.97 
to 2.71, respectively) compared with diabetics on 
metformin. Th   e study was limited by the small number of 
distant recurrences among the diabetics (18 among 
metformin users and 26 among non-metformin users) 
and limited data on metformin use, which were available 
for the adjuvant chemotherapy period only [46].
Among 2,529 breast cancer patients who received neo-
adjuvant chemotherapy for breast cancer at MD Ander-
son, the rate of pathologic complete response was higher 
in the metformin group (24%, n  =  68) compared with 
diabetics who did not take metformin (8%, n = 87) and 
non-diabetics (16%, n = 2,374) (overall P for diﬀ  erence = 
0.02). Metformin was also independently predictive of 
the chances of pathologic complete response (adjusted 
odds ratio = 2.95, 95% CI = 1.07 to 8.17) after adjustment 
for age, diabetes, BMI, stage, grade, ER status, and treat-
ment) [45].
Th  e molecular basis for metformin’s inhibition of 
cancer cell growth is not known but is hypothesized to be 
its ability to inhibit PI3-kinase/AKT/mammalian target 
to rapamycin (mTOR) signaling via activation of the 
LKB1/AMP-activated protein kinase (AMPK) pathway. 
Of all the medications presented in this review article, 
metformin is the only one that will have randomized trial 
data evaluating its eﬀ   ect on breast cancer recurrence 
within the near future. Th   e National Cancer Institutes of 
Canada and US are enrolling subjects for a phase III 
study to evaluate the eﬀ  ect of metformin compared with 
placebo among women with higher-risk stage I and stage 
II or III breast cancer (NCIC MA32). Th   e accrual of this 
study, which opened in April 2010 and is expected to 
close in 2016, is estimated to be 3,852, and the results are 
eagerly awaited. Because of their eﬀ  ects on the PPAR 
pathway, ongoing phase I clinical trials are using a variety 
of thiazolidnediones in combination with chemotherapy 
for advanced solid tumors.
Conclusions
Substantial scientiﬁ  c evidence supports the hypothesis 
that several common and relatively safe drugs may reduce 
breast cancer mortality among breast cancer survivors by 
an amount that rivals the beneﬁ   t of currently used 
therapies. In particular, the evidence is strongest for 
aspirin (approximately 50% reduction), statins (approxi-
mately 25% reduction), and metformin (approximately 
50% reduction).
We believe that randomized trials of aspirin, met-
formin, and statins are essential to move the ﬁ  eld 
forward. Despite the compelling evidence presented in 
this review, it is based primarily on observational studies, 
which are subject to confounding. Th  ese drugs are 
generally safe, and their side eﬀ  ect  proﬁ  les  compare 
favorably with those of drugs used to treat cancer. 
However, we cannot estimate the overall risk-beneﬁ  t 
ratio of these drugs without a randomized trial. For 
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[47] and central nervous system [48] bleeding, and there 
is a suggestion of hepatoxicity with metformin [49]. In 
addition, aspirin is not taken in a ﬁ   xed dose; a 
randomized trial could help to establish the lowest 
eﬀ  ective dose.
If these ﬁ  ndings are conﬁ  rmed in randomized trials 
among breast cancer survivors, the public health impact 
would be immense. We estimate that, if aspirin is 
eﬀ  ective, using it to treat all patients with breast cancer 
in the US could potentially save 10,000 lives per year. In 
addition, if one considers the possible beneﬁ   t in the 
developing world of an inexpensive, widely available 
medicine, the impact is truly staggering; an estimated 
75,000 lives would potentially be saved each year.
In an era in which we struggle to contain health-care 
costs, the extra costs for patients with breast cancer in 
the US would be minimal. For developing countries, it 
could mean the diﬀ  erence between some adjuvant treat-
ment and none. Whereas new cancer treatments typically 
beneﬁ  t only patients in wealthy countries because of the 
costs, these drugs would be a breast cancer treatment 
available to every part of the world. Th   e results of these 
trials could be truly transformative and change the 
treatment of breast cancer across the globe with what 
millions of people already have in their medicine cabinet.
Given the overwhelming weight of the biologic and 
observational data, randomized trials are the deﬁ  nitive 
way to assess the risk-beneﬁ  t balance for breast cancer 
survivors. One such trial is under way for metformin. A 
similar trial for aspirin is deﬁ   nitely warranted, and 
possibly one for statins. We estimate that a trial of aspirin 
would require approximately 3,000 women with stage II 
or III breast cancer randomly assigned 1:1 and followed 
for 5 years and cost approximately $15 million USD. 
However, because these drugs are generic and widely 
available, there is little industry incentive to support such 
studies. We propose that the cost is small given the 
potential beneﬁ  t. Who will ﬁ  ll this need?
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